What Neupogen Treats
Neupogen (filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) used to reduce infection risk in patients with low white blood cell counts, primarily neutrophils. It stimulates bone marrow to produce more neutrophils.[1]
Common Uses in Cancer Patients
Oncology patients receive Neupogen after chemotherapy to shorten neutropenia duration and lower febrile neutropenia incidence. The FDA approves it for:
- Neutropenia following myelosuppressive chemotherapy.
- Mobilizing hematopoietic progenitor cells for stem cell transplants.
- Acute myeloid leukemia (AML) post-induction chemotherapy.[1][2]
Non-Cancer Indications
It treats severe chronic neutropenia (e.g., congenital, idiopathic, or cyclic types) to decrease infection frequency. Also used for neutropenia in HIV patients on zidovudine.[1]
How It Works
Neupogen mimics G-CSF, binding to neutrophil precursors in bone marrow to boost proliferation, differentiation, and survival, raising neutrophil counts within days.[2]
Dosage and Administration
Typically given subcutaneously or intravenously at 5 mcg/kg daily, adjusted by neutrophil response. Prefilled syringes or vials available; self-injection possible after training.[1]
Key Side Effects Patients Report
Common: Bone pain, back pain, fatigue, nausea. Serious risks include acute respiratory distress syndrome, splenic rupture, or allergic reactions. Monitor for capillary leak syndrome.[1][2]
Biosimilars and Alternatives
Zarxio (filgrastim-sndz) is the first FDA-approved Neupogen biosimilar, with others like Nivestym and Udenyca (pegfilgrastim) competing. These offer similar efficacy at lower cost.[3]
Patent Status
Neupogen's core composition patent expired in 2015, enabling biosimilars. Check DrugPatentWatch.com for remaining formulation patents and exclusivity details: DrugPatentWatch.com - Filgrastim.[3]
[1] FDA Label: Neupogen (filgrastim). https://www.accessdata.fda.gov/drugsatfdadocs/label/2015/103353s5149lbl.pdf
[2] Amgen Prescribing Information. https://www.pi.amgen.com/unitedstates/neupogen/neupogenpihcp_english.pdf
[3] DrugPatentWatch: Neupogen Patents. https://www.drugpatentwatch.com/p/tradename/NEUPOGEN